Skip to main content

Professor emeritus Hans Wiksell

Hans Wiksell is professor emeritus in Clinical application of electromagnetic and acoustic energies at the Department of Molecular Medicine and Surgery.


Research group: Breast Surgery

The clinical application of electromagnetic and acoustic energies is an essential development moving away from classical invasive surgery towards a more patient friendly methodology using minimally or non-invasive treatment modalities.

Hans Wiksell has developed the ultrasonic aspirator "Sonocut", the kidney stone fragmentation device (ESWL) "Lithout" and a device for the treatment of benign prostatic hyperplasia based on computer controlled microwave heating (TUMT) called "ECP". More than 400 000 patients worldwide have been successfully treated with these instruments. Today Hans Wiksell is involved in developing new methods for breast cancer diagnosis and therapy.

Breast cancer is today the most common form of cancer in women. With incidences rising and mortality rates remaining virtually unchanged there is a substantial need for new treatment modalities. Working in close collaboration with medical experts Hans Wiksell is driving forward the development towards a more lenient and patient friendly way of breast cancer management.

Preferential Radiofrequency Ablation (PRFA) is a promising new technique for the minimally-invasive treatment of breast cancer. It has shown high success rates and low complication rates while achieving excellent cosmetic results.

Other projects include means to prevent possible tumor cell seeding during diagnostic procedures (AntiSeeding) as well as innovative developments regarding both fine needle aspiration (FNA) and core needle biopsy (CNB).

Diagnostic developments are implemented in a European Project (Fluodiamon) where Hans Wiksell acts as work package leader.

Vilhelm Ekstrand's doctoral thesis "Therapeutic Applications of Acoustic and Electromagnetic Energy".


Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.
Sennerstam R, Franzén B, Wiksell H, Auer G
Cancer Cytopathol 2017 Oct;125(10):748-756

Article about the article: Primum Non Nocere

A new method to gently place biopsy needles or treatment electrodes into tissues with high target precision.
Wiksell H, Löfgren L, Schässburger K, Leifland K, Thorneman K, Auer G
Phys Med 2016 May;32(5):724-7

Minimally-invasive treatment of early stage breast cancer: a feasibility study using radiofrequency ablation under local anesthesia.
Schässburger K, Löfgren L, Lagerstedt U, Leifland K, Thorneman K, Sandstedt B, et al
Breast 2014 Apr;23(2):152-8


Breast cancer and clinical outcome among women over 60 years of age: a plead for more screening and alternative treatments.
Sennerstam R, Wiksell H, Schässburger K, Auer G
Anal Quant Cytopathol Histpathol 2012 Aug;34(4):189-94